National Cancer Institute; Amended Notice of Meeting, 514 [2014-30877]
Download as PDF
<![CDATA[
514
Federal Register / Vol. 80, No. 3 / Tuesday, January 6, 2015 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Therapeutic Agents that Target Cancer Stem
Cells.
Date: March 10–11, 2015.
Time: 11:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
4W032, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Kenneth L. Bielat, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, 9609 Medical Center Drive,
Room 7W244, Bethesda, MD 20892–9750,
240–276–6373, bielatk@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Innovative
Research in Cancer Nanotechnology (IRCN).
Date: March 19–20, 2015.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel and
Conference Center 5701 Marinelli Road
Bethesda, MD 20852.
Contact Person: Kenneth L. Bielat, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, 9609 Medical Center Drive,
Room 7W244, Bethesda, MD 20892–9750,
240–276–6373, bielatk@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Advance
Culture Systems for Expansion of Cancer
Stem Cells.
Date: March 25–26, 2015.
Time: 11:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
2E032, Rockville, MD 20850, (Telephone
Conference Call).
Contact Person: Kenneth L. Bielat, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, 9609 Medical Center Drive,
Room 7W244, Bethesda, MD 20892–9750,
240–276–6373, bielatk@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/sep/sep.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
VerDate Sep<11>2014
19:38 Jan 05, 2015
Jkt 235001
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: December 30, 2014.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Cancer Institute; Amended
Notice of Meeting
[FR Doc. 2014–30879 Filed 1–5–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Initial
Review Group; Neurological Sciences and
Disorders B.
Date: February 19–20, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Monaco Alexandria, 480 King
Street, Alexandria, VA 22314.
Contact Person: Birgit Neuhuber, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
NINDS/NIH/DHHS/Neuroscience Center,
6001 Executive Boulevard, Suite 3208, MSC
9529, Bethesda, MD 20892–9529, 301–496–
3562, neuhuber@ninds.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: December 30, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–30875 Filed 1–5–15; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
National Institutes of Health
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Special Emphasis Panel,
January 29, 2015 10:00 a.m. to January
29, 2015, 05:00 p.m., National Cancer
Institute Shady Grove, 9609 Medical
Center Drive, Rockville, MD 20850
which was published in the Federal
Register on December 30, 2014,
79FR78456.
The meeting notice is being amended
to change the title from Omnibus SEP–
5 to Fundamental Mechanisms of
Affective and Decisional Processes in
Cancer Control. The meeting is closed to
the public.
Dated: December 30, 2014.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–30877 Filed 1–5–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, NIAID Clinical Trial
Implementation Cooperative Agreement
(U01).
Date: January 22, 2015.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3G62A, 5601 Fisher Lane, Rockville, MD
20892, (Telephone Conference Call).
E:\FR\FM\06JAN1.SGM
06JAN1
]]>Agencies
[Federal Register Volume 80, Number 3 (Tuesday, January 6, 2015)]
[Notices]
[Page 514]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-30877]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Cancer Institute Special Emphasis Panel, January 29, 2015 10:00 a.m. to
January 29, 2015, 05:00 p.m., National Cancer Institute Shady Grove,
9609 Medical Center Drive, Rockville, MD 20850 which was published in
the Federal Register on December 30, 2014, 79FR78456.
The meeting notice is being amended to change the title from
Omnibus SEP-5 to Fundamental Mechanisms of Affective and Decisional
Processes in Cancer Control. The meeting is closed to the public.
Dated: December 30, 2014.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-30877 Filed 1-5-15; 8:45 am]
BILLING CODE 4140-01-P
